Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.

Author: Bolland, Mark; Horne, Anne; Briggs, Simon E; Thomas, Mark; Reid, Ian; Gamble, Gregory; Grey, Andrew

Date: 2019-10

Type: Journal article

Link to this item using this URL: http://hdl.handle.net/2292/49133

The University of Auckland Library

Abstract

INTRODUCTION:Most prospective studies of bone mineral density (BMD) in HIV-infected cohorts taking antiretroviral therapy (ART) have been of short duration, typically?????3??years. Such studies have reported short-term stable or increasing BMD. We assessed whether this BMD stability persists for???>???10??years in middle-aged and older men established on ART. METHODS:A 12-year, prospective, longitudinal study in 44 HIV-infected men treated with ART who had measurements of BMD at the lumbar spine, proximal femur and total body at baseline, 2, 6 and 12??years. RESULTS:At baseline, the mean age of participants was 49??years, the mean duration of HIV infection was 8??years, and the mean duration of ART was 50??months. After 12??years, BMD increased by 6.9% (95% CI 3.4 to 10.3) at the lumbar spine, and remained stable (range of BMD change: -???0.6% to 0.0%) at the total hip, femoral neck and total body. Only two individuals had a decrease of???>???10% in BMD at any site during follow-up and both decreases in BMD were explained by co-morbid illnesses. CONCLUSIONS:BMD remained stable over 12??years in middle-aged and older HIV-infected men treated with ART. Monitoring BMD in men established on ART who do not have risk factors for BMD loss is not necessary.

Citation: ["Calcified tissue international 105(4):423-429 Oct 2019"]

Copyright: https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm